FBP2抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P08321(FBP2 Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08321(FBP2 Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

The FBP2 antibody targets fructose-1.6-bisphosphatase 2 (FBP2), a mitochondrial enzyme involved in gluconeogenesis by catalyzing the hydrolysis of fructose-1.6-bisphosphate to fructose-6-phosphate. Unlike its cytosolic isoform FBP1. FBP2 is primarily expressed in muscle and brain tissues and plays dual roles in energy metabolism regulation. Beyond gluconeogenesis, FBP2 influences cellular processes such as apoptosis, oxidative stress response, and mitochondrial function. Recent studies highlight its tumor-suppressive role in cancers, where FBP2 downregulation correlates with metabolic reprogramming (e.g., Warburg effect) and cancer progression. Loss of FBP2 promotes glycolysis, proliferation, and metastasis in various malignancies, including breast, liver, and lung cancers.

FBP2 antibodies are critical tools for detecting protein expression levels in research applications like Western blotting, immunohistochemistry, and immunofluorescence. They help elucidate FBP2's tissue-specific distribution, subcellular localization, and dynamic expression changes under pathological conditions. Commercially available antibodies vary in clonality (monoclonal/polyoclonal) and host species, with validation data essential to ensure specificity. Ongoing research leverages these antibodies to explore FBP2's therapeutic potential in metabolic disorders and cancer, aiming to restore its expression or activity as a treatment strategy. Proper antibody validation remains crucial due to cross-reactivity risks with FBP1 or other isoforms.